OBJECTIVE:
To systematically summarize the literature on maternal influenza vaccination and the risk for congenital malformations using the methodology of meta-analysis.
DATA SOURCES: PubMed, Scopus, and Embase databases (up to December 2014) as well as ClinicalTrials.gov (May 2015) and references of relevant articles were searched. The search strategy included combinations of the terms "influenza," "vaccin*," "pregnan*," "safe*," "adverse," "congenital," "malformation," "defect," and "anomal*."
METHODS OF STUDY SELECTION:
Eligible studies examined the association between antepartum or preconceptional maternal immunization with inactivated influenza vaccines (seasonal trivalent or monovalent H1N1) and the risk for congenital malformations. Studies with no or inappropriate control group (comparison with population background rates or other vaccine types) were excluded.
TABULATION, INTEGRATION, AND RESULTS:
The risk for congenital anomalies after influenza vaccination was examined in 15 studies: 14 18 ; eight studies; I 2 50). When assessing only major malformations, no increased risk was detected after immunization at any trimester (OR 0.99, 0.88-1.11; 12 studies; I 2 531.5) or at the first trimester (OR 0.98, 0.83-1.16; seven studies; I 2 50). Neither adjuvanted (OR 1.06, 0.95-1.20; five studies; I 2 518.8) nor unadjuvanted vaccines (OR 0.89, 0.75-1.04; seven studies; I 2 522.6) were associated with an increased risk for congenital defects.
CONCLUSION: This systematic review did not indicate an increased risk for congenital anomalies after maternal influenza immunization adding to the evidence base on the safety of influenza vaccination in pregnancy. P regnant women are at increased risk for hospitalization, death, and adverse pregnancy outcomes after influenza infection. [1] [2] [3] [4] [5] Therefore, routine immunization against influenza is recommended for women who will be pregnant during the influenza season. 6, 7 Evidence from randomized controlled trials suggests that antenatal immunization against influenza confers protection of both the mother and the newborn from influenza infection. 8, 9 However, vaccination rates among pregnant women remain low mainly as a result of concerns about the safety of the influenza vaccine. 10 Influenza vaccines are available either as liveattenuated-contraindicated during pregnancy-or as inactivated (treated with formaldehyde, b-propiolactone, detergent, ultraviolet irradiation) formulations. [11] [12] [13] During the 2009 H1N1 pandemic, a monovalent inactivated vaccine was available for maternal immunization. Currently, seasonal inactivated vaccines containing antigens from three (trivalent) or four (quadrivalent) influenza strains are recommended for pregnant women by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. 14 Since 2004, the Advisory Committee on Immunization Practices recommends that pregnant women be vaccinated against influenza at any stage of gestation, including the first trimester. 15 A number of studies sought to assess the safety of antenatal influenza immunization. However, most of these investigations are limited by their small sample size, which obscures the evaluation of rare events such as pregnancy loss and congenital malformations. Two recent systematic reviews suggested that antenatal influenza vaccination is safe with regard to spontaneous abortions, stillbirths, and preterm deliveries. 16, 17 The aim of the present study was to systematically summarize the evidence on the risk for congenital malformations in fetuses of women vaccinated with inactivated influenza vaccines during pregnancy compared with those of unvaccinated pregnant women.
SOURCES
The systematic review has been conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines. 18 Three investigators (K.A.P., A.A.K., C.E.P.) independently conducted a systematic literature search on PubMed, Embase, and Scopus databases up to December 2014. The search strategy included combinations of the following search terms: "influenza," "vaccin*," "pregnan*," "safe*," "adverse," "congenital," "malformation," "defect," and "anomal*." After screening the title and abstract, potentially relevant studies were selected for further evaluation in full text. The same search strategy was used in ClinicalTrials.gov (May 2015). References of relevant articles were also searched to identify additional studies.
STUDY SELECTION
To be considered for inclusion in the systematic review, a study should have examined the association between maternal vaccination with an inactivated influenza vaccine (either seasonal trivalent or monovalent H1N1, either adjuvanted or nonadjuvanted) during pregnancy or immediately before conception and congenital malformations. Studies with no or an inappropriate control group (eg, studies comparing outcomes with population background rates, studies comparing influenza vaccine with other vaccine types) were excluded. Only studies published in peerreviewed journals were considered for inclusion. Abstracts, posters, book chapters, recommendations, review articles, and animal studies were excluded. Publications in languages other than English were not eligible for inclusion.
Two reviewers (K.A.P., A.A.K.) independently extracted the following data: first author, year of publication, country, influenza season, design, study population, effect estimates (odds ratios [ORs] ) and 95% confidence intervals (CIs) of vaccine exposure, and potential confounding factors that were controlled by design or analysis. When several effect estimates were reported, that with the highest degree of control for confounding factors was selected. The quality of the eligible studies was assessed by use of the NewcastleOttawa scale. 19 Any disagreement was resolved by consensus in meetings that involved all authors.
Odds ratios and 95% CIs of studies that did not report effect estimates were calculated using OpenEpi. 20 Meta-analyses were conducted using Comprehensive Meta Analysis 2. Pooled ORs and 95% CIs were calculated by use of the DerSimonian-Laird random-effects model. 21 Heterogeneity was assessed by using the I 2 statistic and was considered significant if I 2 30% or greater. 22 The primary outcome was congenital malformations 1) in the total study population vaccinated at any trimester; and 2) in the subgroup exposed at the first trimester of pregnancy. A secondary analysis was conducted focusing on major congenital defects as defined by each study; for studies that did not specify whether they examined major or any malformation, we excluded minor defects according to the European registry for congenital anomalies and twins (EUROCAT). 23 Publication bias was assessed by inspection of funnel plots. 24 Sensitivity analysis was performed by excluding an old study (H1N1 A/New Jersey/76 vaccine) probably using a wide definition for congenital anomalies. 25 We also conducted subgroup analyses with regard to the use of adjuvanted or unadjuvanted vaccines and the control (by design or analysis) of at least two potential confounding factors.
RESULTS
The literature search yielded a total of 2,003 records. After exclusion of duplicates and irrelevant studies, 90 potentially eligible studies were assessed in full text and 15 studies were included in the systematic review ( Fig. 1) . [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Of the included studies, 10 assessed a monovalent H1N1 2009 pandemic vaccine, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] two studies addressed a seasonal trivalent influenza vaccine, 38, 39 two included both, 36, 37 whereas an early study explored a monovalent H1N1 (A/New Jersey/ 76) vaccine 25 ( Table 1) . Twelve studies provided data on major congenital defects (Appendix 1, available online at http://links.lww.com/AOG/A694). Seven studies did not address confounding, 25, [27] [28] [29] 35, 37, 38 whereas one study controlled only for age 34 ( Table 2 ). Maternal immunization during the first trimester was explored by eight studies, 27, [30] [31] [32] [33] 35, 36, 38 of which three reported adjusted effect estimates. 30, 32, 36 Of the 10 included studies investigating the H1N1 2009 pandemic vaccine, none demonstrated a significant risk of congenital anomalies. One study in Italy, which compared 6,131 pregnant women immunized at the second or third trimester with 23,987 matched women in a control group, showed small, nonsignificant, but positive ORs overall (adjusted OR 1.14, 0.99-1.31) and for heart defects specifically (adjusted OR 1.22, 0.98-1.51) in children born to vaccinated women. 26 No associations between maternal influenza vaccination and congenital birth defects were found in studies in Germany, 33 France, 29 the Netherlands, 31 Sweden, 30 Denmark, 32 Scotland, 35 Ireland, 27 Argentina, 28 and Taiwan. 34 Two studies provided adjusted effect estimates for congenital anomalies after firsttrimester exposure. 30, 32 Källén et al 30 found that 3,165 neonates exposed during the first trimester were not at increased risk for congenital anomalies compared with neonates in the unexposed control group. In propensity score-matched analysis of 660 neonates (330 exposed), Pasternak et al showed that first-trimester exposure was not associated with major birth defects. 36,37 A prospective cohort study investigated the safety of first-trimester immunization in 328 vaccinated and 188 unvaccinated women and found no increased risk for major malformations. 36 In a case-control study including 3,104 malformed case participants and 1,087 control participants, maternal influenza vaccination did not increase the rate of overall congenital anomalies. Notably, logistic regression analysis of specific defects found an increased risk for anopthalmia or micropthalmia in neonates of exposed women (OR 8.67, 1.10-68.5). However, this estimate was based on very few cases and had wide CIs. 37 Two retrospective cohort studies in the United States examined the potential teratogenicity of antenatal immunization with seasonal trivalent influenza vaccines. 38, 39 The first study (1998) (1999) (2000) (2001) (2002) (2003) ) compared 225 pregnant women vaccinated at the second or third trimester with a control group of 826 unvaccinated pregnant women matched by age, month of delivery, and type of medical insurance. No congenital defects were reported in the vaccinated group compared with 15 (1.8%) events in the control group. 39 The second study (2003) (2004) (2005) (2006) (2007) (2008) , including 8,864 immunized and 76,919 unimmunized pregnant women, found no increased risk for major malformations regardless of trimester of vaccination. Importantly, a separate analysis showed no association between first-trimester exposure and congenital anomalies. 38 During a national immunization program in the United States in 1976-1977, a prospective study investigated the safety of monovalent inactivated influenza A/New Jersey/76 virus vaccine during pregnancy. 25 In Fig. 1 . Flow diagram of the study selection process. (Fig. 2B) . In a secondary analysis addressing major birth defects, no association was detected either after Unauthorized reproduction of this article is prohibited. Finally, the results of the meta-analyses did not change after exclusion of the early study on monovalent inactivated A/New Jersey/76 influenza vaccine (data not shown). 25 Neither adjuvanted (OR 1.06, 0.95-1.20; five studies; I 2 518.8) nor unadjuvanted vaccines (OR 0.89, 0.75-1.04; seven studies; I 2 522.6) were associated with congenital malformations (Fig. 3) . In subgroup analysis based on the adjustment of confounding bias, anytrimester vaccination did not increase the risk for congenital defects in studies that controlled for confounders (OR 1.07, 0.98-1.18; seven studies; I 2 50) and was protective in studies not addressing confounding (OR 0.87, 0.79-0.96; eight studies; I 2 50) (Appendix 5A, available online at http://links.lww.com/AOG/ A698). Regarding first-trimester exposure, no increased risk for malformations was found in either studies that controlled for confounding (OR 1.00, 0.87-1.16; three studies; I 2 50) or those that did not (OR 1.28, 0.88-1. 88; five studies; I 2 50) (Appendix 5B, available online at http://links.lww.com/AOG/A698).
DISCUSSION
In view of the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommendations on routine immunization of pregnant women at any time during pregnancy, found no association between maternal influenza vaccination at any trimester, including the first, and overall or major congenital malformations. No association was also obtained in subgroup analyses with regard to the use of adjuvants and the control of confounding. The first trimester of pregnancy is the crucial period of organogenesis, and therefore many obstetricians administer the influenza vaccine later in the course of pregnancy. Based on eight studies (4,733 vaccinated compared with 196,054 unvaccinated), our metaanalysis did not indicate an increased risk for malformations associated with first-trimester exposure. Importantly, none of the three studies adjusting for confounding indicated an association between firsttrimester exposure and major birth defects. 30, 32, 36 A limitation is that our analysis was dominated by one large study, 30 thus underscoring the need for further studies assessing first-trimester immunization.
In a previous meta-analysis of seven studies, Jefferson and colleagues 40 assessed potential harms associated with influenza vaccination during pregnancy and found no increased risk for congenital malformations. Our meta-analysis including 15 studies updates this earlier study, which analyzed total (major and minor) anomalies associated with maternal vaccination at any trimester. In addition, our analysis addressed first-trimester exposure and major congenital malformations adding to the evidence on the safety of maternal influenza immunization. Adjuvants-compounds that enhance the immune response to vaccination-are frequently used during pandemics as means to spare antigen and meet the demand for mass production. Such compounds have been used for decades in various vaccine types with no evidence of serious or long-term adverse events. 41 During the H1N1 2009 pandemic outbreak, adjuvanted influenza vaccines were licensed in Europe and Canada and administered in pregnant women without being linked with excessive reactogenicity or adverse pregnancy outcomes. 26, [30] [31] [32] 42 In the current meta-analysis, neither adjuvanted nor unadjuvanted influenza vaccines were associated with increased risk for congenital anomalies.
Trotta et al 26 reported a nonsignificant increase in congenital heart defects associated with antenatal influenza immunization. Importantly, nearly 99% of immunized women in this study were vaccinated during the second and third trimesters. The fact that the majority of such defects occur during the first 10 weeks of pregnancy renders a causal association unlikely. Moreover, vaccination was more likely to be administered to women with comorbidities-confounders that may affect the effect estimates if not adequately adjusted. The importance of comparability of study arms in observational studies is illustrated by the heterogeneity between studies with or without confounding bias.
It should be mentioned that there was a limited number of studies assessing trivalent influenza vaccines; the majority of the included studies assessed the monovalent H1N1 2009 pandemic vaccine. A retrospective study among pregnant U.S. military women found similar rates of major birth defects in more than 16,000 newborns exposed either to H1N1 2009 pandemic vaccine or trivalent influenza vaccine (2.1% compared with 2%, respectively; adjusted OR 1.08, 0.87-1.35). 43 In addition, this systematic review excluded studies using population background rates as reference for comparisons. Such studies did not report higher rates of congenital defects after influenza vaccination during pregnancy. 42, 44, 45 This meta-analysis has several limitations. First, modest statistical heterogeneity was detected in the analysis of congenital anomalies after vaccination at any trimester of pregnancy. Notably, heterogeneity decreased in a separate analysis of H1N1 2009 pandemic vaccines or in subgroup analysis of adjuvanted compared with unadjuvanted formulations and disappeared after excluding studies that did not address confounding. Second, studies assessing the monovalent H1N1 2009 pandemic vaccine dominated in our pooled analysis. Third, the total number of firsttrimester exposed patients in our analysis might not have provided the power to detect small effects, and few studies addressing confounding explored firsttrimester vaccination. Finally, in the case-control study providing data on influenza seasons 2009-2010 and 2010-2011 separately, we added the numbers although there was a small overlap between seasons. 37 In conclusion, this systematic review provided additional evidence on the safety of influenza vaccination during pregnancy with regard to congenital malformations. Given the methodologic limitations of observational studies, further research focusing primarily on the risk of first-trimester immunization with trivalent influenza vaccines and adjusting for potential confounders is warranted to better characterize the safety of immunization of pregnant women and increase the vaccination coverage in this high-risk group.
